Galapagos NV 2025 AR2
The report details the strategic transformation of the company during 2025, including the decision to wind down its cell therapy activities and refocus on transformational business development in oncology and immunology. Financially, the company achieved an operating profit of €295.0 million, primarily driven by the recognition of €1,069.0 million in deferred collaboration revenue from Gilead. The company ended the year with a robust cash and financial investments position of approximately €3.0 billion. Additionally, the report highlights key clinical progress, including positive Phase 2 results for the TYK2 inhibitor GLPG3667 in dermatomyositis.
Company: Galapagos NV
Sector: Health Care
Country: Belgium
Year: 2025
Type: AR2
Pages: 249
Galapagos NV
Annual Report
The report details the strategic transformation of the company during 2025, including the decision to wind down its cell therapy activities and refocus on transformational business development in oncology and immunology. Financially, the company achieved an operating profit of €295.0 million, primarily driven by the recognition of €1,069.0 million in deferred collaboration revenue from Gilead. The company ended the year with a robust cash and financial investments position of approximately €3.0 billion. Additionally, the report highlights key clinical progress, including positive Phase 2 results for the TYK2 inhibitor GLPG3667 in dermatomyositis.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Women on Board
Employees